In the ongoing phase II study, Celldex enrolled 120 patients with advanced breast cancer that over-expresses GPNMB (confirmed by an independent test). The patients, all of whom no longer respond to currently approved treatments, are then randomized to receive either CDX-011 or a physician's choice of treatment. The primary endpoint of the study is overall response rate.
Celldex CEO Anthony Marucci told me last week that a meaningful and positive response rate in the study would be 12% to 15% with a progression-free survival of greater than 12 weeks. Celldex is developing CDX-011 with a companion diagnostic that measures levels of GPNMB. As I said above, data from the phase II study is expected this spring at the American Society of Clinical Oncology annual meeting. It's a very important catalyst for Celldex.
Gary D. asks, "Do you feel any better about Avanir Pharmaceuticals (AVNR) yet or is 2012 going to be a repeat of 2011? They really blew it on having enough insurance coverage for patients who wanted to use Nuedexta but couldn't afford it or their insurance or Medicare didn't cover it, but as of January 1st, it looks a lot better. They turned their focus to long-term care facilities which should help, and of course with almost a year under their belt they should have got through some of the bumps and bruises."
Avanir had a rough year, no doubt. The launch of Nuedexta for pseudobulbar affect (PBA) disappointed, with fiscal 2011 net sales of $6.1 million well below expectations. Avanir shares lost half of their value as a result.This year has to be better for Avanir. Could it be any worse? The company appears to have learned some hard lessons and is making changes like adding sales reps to target long-term care facilities and assisting patients with reimbursement and co-payment issues which should help grow Nuedexta sales this year. Expectations have come down to more sensible levels. Short sellers, at least the few I know who were involved in the stock last year (profitably), have moved on.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV